Literature DB >> 16263820

Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism.

E Carmina1, F Rosato, A Jannì, M Rizzo, R A Longo.   

Abstract

CONTEXT: We undertook this study to estimate the prevalence of the various androgen excess disorders using the new criteria suggested for the diagnosis of polycystic ovary syndrome (PCOS).
SETTING: The study was performed at two endocrine departments at the University of Palermo (Palermo, Italy). PATIENTS: The records of all patients referred between 1980 and 2004 for evaluation of clinical hyperandrogenism were reevaluated. All past diagnoses were reviewed using the actual diagnostic criteria. To be included in this study, the records of the patients had to present the following available data: clinical evaluation of hyperandrogenism, body weight and height, testosterone (T), free T, dehydroepiandrosterone sulfate, 17-hydroxyprogesterone, progesterone, and pelvic sonography. A total of 1226 consecutive patients were seen during the study period, but only the scores of 950 patients satisfied all criteria and were reassessed for the diagnosis.
RESULTS: The prevalence of androgen excess disorders was: PCOS, 72.1% (classic anovulatory patients, 56.6%; mild ovulatory patients, 15.5%), idiopathic hyperandrogenism, 15.8%; idiopathic hirsutism, 7.6%; 21-hydroxylase-deficient nonclassic adrenal hyperplasia, 4.3%; and androgen-secreting tumors, 0.2%. Compared with other androgen excess disorders, patients with PCOS had increased body weight whereas nonclassic adrenal hyperplasia patients were younger and more hirsute and had higher serum levels of T, free T, and 17-hydroxyprogesterone.
CONCLUSIONS: Classic PCOS is the most common androgen excess disorder. However, mild androgen excess disorders (ovulatory PCOS and idiopathic hyperandrogenism) are also common and, in an endocrine setting, include about 30% of patients with clinical hyperandrogenism.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16263820     DOI: 10.1210/jc.2005-1457

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  65 in total

1.  Assessing cardiovascular risk in Mediterranean women with polycystic ovary syndrome.

Authors:  M Rizzo; R A Longo; E Guastella; G B Rini; E Carmina
Journal:  J Endocrinol Invest       Date:  2010-10-15       Impact factor: 4.256

Review 2.  Visually scoring hirsutism.

Authors:  Bulent O Yildiz; Sheila Bolour; Keslie Woods; April Moore; Ricardo Azziz
Journal:  Hum Reprod Update       Date:  2010 Jan-Feb       Impact factor: 15.610

Review 3.  The Polycystic Ovary Morphology-Polycystic Ovary Syndrome Spectrum.

Authors:  Robert L Rosenfield
Journal:  J Pediatr Adolesc Gynecol       Date:  2014-08-27       Impact factor: 1.814

4.  Virilising ovarian tumour in a woman with an adrenal nodule.

Authors:  Maria Luisa Cecilia Rivera-Arkoncel; Debby Pacquing-Songco; Frances Lina Lantion-Ang
Journal:  BMJ Case Rep       Date:  2010-12-14

5.  "Occult" ovarian Leydig cell tumor: when laboratory tells more than imaging.

Authors:  Rosa Maria Paragliola; Francesco Torino; Paola Senes; Laura Castellino; Vanda Salutari; Alfredo Pontecorvi; Giovanni Scambia; Salvatore M Corsello
Journal:  Endocrine       Date:  2013-10-04       Impact factor: 3.633

6.  Effect of glucocorticoid-induced insulin resistance on follicle development and ovulation.

Authors:  Katherine S Hackbart; Pauline M Cunha; Rudelle K Meyer; Milo C Wiltbank
Journal:  Biol Reprod       Date:  2013-06-20       Impact factor: 4.285

7.  Nonclassic congenital adrenal hyperplasia.

Authors:  Selma Feldman Witchel; Ricardo Azziz
Journal:  Int J Pediatr Endocrinol       Date:  2010-06-30

Review 8.  The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited.

Authors:  Robert L Rosenfield; David A Ehrmann
Journal:  Endocr Rev       Date:  2016-07-26       Impact factor: 19.871

9.  Study of RNA interference inhibiting rat ovarian androgen biosynthesis by depressing 17alpha-hydroxylase/17, 20-lyase activity in vivo.

Authors:  Yi Li; Xiao-yan Liang; Li-na Wei; Yong-lao Xiong; Xing Yang; Hui-gan Shi; Zi-hong Yang
Journal:  Reprod Biol Endocrinol       Date:  2009-07-17       Impact factor: 5.211

10.  Hirsutism: clinico-investigative profile of 50 Indian patients.

Authors:  Nand Lal Sharma; Vikram K Mahajan; Rashmi Jindal; Mudita Gupta; Anju Lath
Journal:  Indian J Dermatol       Date:  2008       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.